Novo Nordisk A/S
Health misinformation is lowering U.S. life expectancy, FDA Commissioner Robert Califf says
Life expectancy in the U.S. is between three and five years lower than the average in other high-income countries — and the gap comes in part from misinformation, Food and Drug Administration Commissioner Dr. Robert Califf said. “It’s looking worse, not better, over the last several years,” Califf told CNBC in an interview Thursday at […]
Read More
People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication
This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”. Joel Saget | AFP | Getty Images Patients taking blockbuster obesity drugs Ozempic or Wegovy will pack the pounds back on after they stop taking the medications. “I think this is what we […]
Read More
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk
A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters Sanofi on Thursday said it’s planning to cut the U.S. price of its most popular insulin drug by 78% and cap monthly out-of-pocket costs at $35 for people […]
Read More
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
Novo Nordisk Inc. NovoLog brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Alex Flynn | Bloomberg | Getty Images Novo Nordisk on Tuesday announced plans to slash the price of several insulin drugs by up to 75% in the U.S., becoming the […]
Read More
Under threat, Weight Watchers enters obesity drug space. Here’s what it means for the stock
WW International is steering hard in a new direction, hoping to turn the growing interest in obesity medications to its advantage. On paper, the new strategy could be the answer to its problems, but significant execution risks remain. Shares of the Weight Watchers parent are up nearly 50% on Tuesday after the company announced plans […]
Read More
This biotech startup has a possibility to get a piece of the profitable obesity drug market, analysts say
It really is been challenging to pass up the buzz about a new course of weight problems remedies , but 1 massive disadvantage to these therapies is that they involve a weekly injection. Enter biotech startup Composition Therapeutics , which is hoping to change that routine with oral GLP-1 formulations for being overweight and kind […]
Read More
Strategist states it’s the ‘last phase’ of the bear marketplace — and names 3 shares to obtain right now
Shares are in the “very last stage” of the bear marketplace — and buyers should really search forward to the next fifty percent of 2023, a person analyst suggests. “We are kind of in the past period of the bear market place,” stated James Demmert, main expenditure officer at Main Street Analysis. “That previous stage […]
Read More
Biden proposal to cap all insulin prices at $35 a month has little chance of passing Congress
President Joe Biden delivers the State of the Union address to a joint session of Congress on Feb. 7, 2023 Pool | Getty Images President Joe Biden used the bully pulpit during the State of the Union address this week to call for a universal price cap on insulin for all diabetes patients but the […]
Read More
Eli Lilly investors spooked by weak Mounjaro sales, but it’s the obesity drug approval that will unlock its value
The demand is there, but so are the hurdles. Eli Lilly investors got a reality check on Thursday, as the stock tumbled more than 6%. Hopes have been running high for the company’s recently launched Mounjaro. Right now, the drug has been approved to treat type 2 diabetes, but many expect sales to really take […]
Read More